Drugs / Levosulpiride

Trials 3 · a red edge is where a trial was stopped

2009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT02481583 Mar → May 2013 dyspepsia Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Completed No outcome recorded
Phase 21 trial
Phase 2 NCT03161652 May 2017 → Dec 2026 expected diabetic macular edema Carmen Clapp Recruiting No outcome recorded
Phase 2/31 trial
Phase 2/3 NCT00866645 Feb 2009 → Jul 2010 Shanghai Mental Health Center Completed No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
NCT04697641 Comparator Sep 2017 → May 2019 Helicobacter pylori infectious disease, dyspepsia Sir Ganga Ram Hospital Completed No outcome recorded

Evidence & citations 15 cited values

Every value below carries the sentence it was read from. 5 sources stand behind the page.

FieldValueCited text
Known as Levosulpiride ClinicalTrials.gov intervention name — accepted as the source's own label NCT00866645
3

NCT03161652

NCT02481583

NCT04697641

Known as L-sulpiride ChEMBL registry synonym — accepted as the source's own label CHEMBL267044
Known as Lesuride ChEMBL registry synonym — accepted as the source's own label CHEMBL267044
Known as Levobren ChEMBL registry synonym — accepted as the source's own label CHEMBL267044
Known as Levopraid ChEMBL registry synonym — accepted as the source's own label CHEMBL267044
Known as Levopride ChEMBL registry synonym — accepted as the source's own label CHEMBL267044
Known as Levosulpirida ChEMBL registry synonym — accepted as the source's own label CHEMBL267044
Known as S-(-)-sulpiride ChEMBL registry synonym — accepted as the source's own label CHEMBL267044
Known as Sulpiride l-form ChEMBL registry synonym — accepted as the source's own label CHEMBL267044
Action Activate “Serotonin 4 (5-HT4) receptor agonist” CHEMBL267044
Action Inhibit “The trial investigates a new specific therapy for DR and DME based on elevating the circulating levels of prolactin with the prokynetic, dopamine D2 receptor blocker, levosulpiride.” NCT03161652
1

“Dopamine D2 receptor antagonist” CHEMBL267044

Modality Small molecule CHEMBL267044
Route Intramuscular Intramuscular Levosulpiride” NCT00866645
Target DRD2 “Dopamine D2 receptor antagonist” CHEMBL267044
Target HTR4 “Serotonin 4 (5-HT4) receptor agonist” CHEMBL267044